Drug repurposing of antidiabetic agents against COVID-19’s 3CLpro enzyme

Document Type : Research articles

Authors

Pharmaceutical Chemistry Department, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, Egypt.

Abstract

Introduction:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was the etiological agent responsible for the 2019-2020 viral pneumonia outbreak of coronavirus disease, in such a pandemic, it is important to utilize time-saving strategies like drug repurposing, which saves time and money.
Objective:
To repurpose antidiabetic agent(s) that can combat SARS-COV-2, which could benefit diabetic patients infected with the virus while saving the time and money needed for the discovery of novel agents.
Methods:
In the present study, 23 antidiabetic drugs were docked against the active site of SARS-CoV-2 3CL Pro (PDB ID: 7WOF) using BIOVIA Discovery Studio (BIOVIA DS) software, to investigate the inhibitory activity of tested antidiabetic drugs.
Results:
Gliflumide revealed higher activity than the co-crystalized ligand, 5IZ (-45.78 kcal/mol), with CDOCKER values of (-46.58 kcal/mol). Glicetanile and Gliquidone revealed CDOCKER values of (-41.09 and -40.16 kal/mol respectively). Gliflumide seems to have the potential to be a promising ligand against SARS-CoV-2, and thus it requires further validation by in vitro studies.

Keywords

Main Subjects

Files

Share

How to cite

Statistics